{'fraction_non_alphanumeric': 0.04481369587109768, 'fraction_numerical': 0.012084592145015106, 'mean_word_length': 5.735593220338983, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Unaltered immunocompetence in patients with nondisseminated breast cancer at the time of diagnosis

Immunologic parameters were examined preoperatively in 104 patients with breast cancer, staged according to the TNM classification and in 95 age‐matched healthy women. The immunologic evaluation in the peripheral blood included lymphocyte and monocyte counts, determination of E‐rosette‐forming T‐lymphocytes (SER+) and B‐lymphocytes (MER+), T‐lymphocyte subsets defined with monoclonal antibodies (Leu‐1, Leu‐2a, Leu‐3a) and with lectin fractionation (soybean agglutinin), lymphocyte transformation test with phytohemagglutinin (PHA) and concanavalin A (ConA), and colony formation of T‐lymphocytes in agar (T‐lymphocyte colony‐forming cells, [TL‐CFC]). Two age groups (Group A: 30–50 years; Group B: 51–70 years) and the different tumor stages (Stage I‐IV) were analyzed. Patients and controls did not differ in the absolute numbers of lymphocytes, T‐ and B‐cells. In patients of Group B, the absolute number of monocytes was increased slightly in Stage II and III and significantly in Stage IV (P < 0.05). Similarly, the lymphocyte response to PHA was significantly reduced in Stage IV Group B only (P < 0.05). ConA‐induced lymphocyte proliferation and TL‐CFC capacity were not different in patients and controls. In the small number of patients and age‐matched controls in whom T‐lymphocyte subsets were determined, the absolute numbers of T‐cells with helper or suppressor phenotype as defined with Leu‐3a, Leu‐2a, or lectin fractionation with soybean agglutinin were similar. This study demonstrates that in patients with early breast cancer (Stage I‐III), immunocompetence as defined by either functional in vitro studies or surface marker analysis is not significantly altered at the time of diagnosis. In contrast, patients with advanced disease (Stage IV) show a significant increase in the absolute number of monocytes and a depressed PHA responsiveness of mononuclear cells.